Annovis Bio, Inc. (ANVS): who owns it and who trades it
As of Nov 16, 2026, ANVS insiders reported 13 purchases worth $7.1M in the last 12 months. The largest buyer was Michael B Hoffman (Director), with $7.1M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Annovis Bio
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ANVS
61 funds and institutions reported ANVS shares worth $20.2M at the end of Q2 2026, about 38% of the company. The largest holder is Empery Asset Management, LP with 8.5%.
Funds and institutions (13F) 38%Everyone else 62%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Empery Asset Management, LP | 2.40M | 8.47% | $4.5M | New |
| Marshall Wace, LLP | 1.84M | 6.50% | $3.4M | +55% |
| Vanguard Capital Management LLC | 1.65M | 5.81% | $3.1M | +89% |
| Tudor Investment Corp Et Al | 1.36M | 4.79% | $2.5M | New |
| Renaissance Technologies LLC | 1.00M | 3.53% | $1.9M | +188% |
| Two Sigma Investments, LP | 579,571 | 2.04% | $1.1M | -8% |
| Geode Capital Management, LLC | 283,817 | 1.00% | $528K | +15% |
| BlackRock, Inc. | 249,856 | 0.88% | $465K | +79% |
| Citadel Advisors LLC | 243,682 | 0.86% | $453K | New |
| Vanguard Fiduciary Trust Co | 177,530 | 0.63% | $330K | +34% |
| Susquehanna International Group, LLP | 146,804 | 0.52% | $273K | -33% |
| Quadrature Capital Ltd | 90,884 | 0.32% | $169K | New |
| State Street Corp | 77,735 | 0.27% | $145K | No change |
| Northern Trust Corp | 68,070 | 0.24% | $127K | -52% |
| First National Trust Co | 60,000 | 0.21% | $112K | +50% |
| Sherry Group, Inc. | 57,270 | 0.20% | $107K | No change |
| Gsa Capital Partners LLP | 49,904 | 0.18% | $93K | +10% |
| Greenwich Wealth Management LLC | 48,400 | 0.17% | $90K | +3% |
| Headlands Technologies LLC | 48,071 | 0.17% | $89.4K | New |
| Wescott Financial Advisory Group, LLC | 41,607 | 0.15% | $77.4K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ANVS insiders reported $7.1M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Michael B Hoffman | Director | Purchase | 5.00M | $1.00 | $5M | Form 4 |
| May 20, 2026 | Michael B Hoffman | Director | Purchase | 54,933 | $1.90 | $104K | Form 4 |
| May 20, 2026 | Michael B Hoffman | Director | Purchase | 2,562 | $1.75 | $4.5K | Form 4 |
| May 20, 2026 | Michael B Hoffman | Director | Purchase | 18,849 | $1.80 | $33.9K | Form 4 |
| Apr 2, 2026 | Michael B Hoffman | Director | Purchase | 713,800 | $2.10 | $1.5M | Form 4 |
| Dec 8, 2025 | Michael B Hoffman | Director | Purchase | 15,000 | $4.24 | $63.6K | Form 4 |
| Dec 8, 2025 | Michael B Hoffman | Director | Purchase | 30,000 | $4.34 | $130K | Form 4 |
| Nov 24, 2025 | Michael B Hoffman | Director | Purchase | 1,489 | $4.13 | $6.1K | Form 4 |
| Nov 24, 2025 | Michael B Hoffman | Director | Purchase | 28,096 | $4.15 | $117K | Form 4 |
| Nov 24, 2025 | Michael B Hoffman | Director | Purchase | 415 | $4.14 | $1.7K | Form 4 |
| Nov 24, 2025 | Michael B Hoffman | Director | Purchase | 9,200 | $3.85 | $35.4K | Form 4 |
| Nov 21, 2025 | Michael B Hoffman | Director | Purchase | 10,000 | $3.49 | $34.9K | Form 4 |
| Nov 21, 2025 | Michael B Hoffman | Director | Purchase | 10,000 | $3.50 | $35K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael B Hoffman | Director | $7.1M | – | Nov 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ANVS short interest
High short interest. 12.6% of ANVS shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 15%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.36M ANVS shares were sold short, 12.6% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 790,972 shares, buying them all back would take about 6.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.36M | 12.57% | -6% | 790,972 | 6.8 |
| Oct 15, 2026 | 5.72M | 13.43% | -3% | 686,157 | 8.3 |
| Sep 30, 2026 | 5.90M | 13.84% | -2% | 990,573 | 6.0 |
| Sep 15, 2026 | 6.02M | 14.13% | +21% | 1.89M | 3.2 |
| Aug 31, 2026 | 4.99M | 11.71% | +1% | 520,405 | 9.6 |
| Aug 14, 2026 | 4.96M | 11.65% | -4% | 608,131 | 8.2 |
| Jul 31, 2026 | 5.19M | 18.31% | -5% | 549,684 | 9.4 |
| Jul 15, 2026 | 5.45M | 19.22% | +12% | 1.08M | 5.0 |
| Jun 30, 2026 | 4.86M | 17.16% | +1% | 908,320 | 5.4 |
| Jun 15, 2026 | 4.80M | 16.94% | -4% | 1.19M | 4.0 |
| May 29, 2026 | 5.02M | 17.71% | +7% | 1.60M | 3.1 |
| May 15, 2026 | 4.67M | 16.49% | -3% | 964,619 | 4.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Annovis Bio company events
Annovis Bio filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementAnnovis Bio, Inc. entered into an Underwriting Agreement, dated as of November 5, 2026, with Canaccord Genuity LLC, as underwriter, pursuant to which the Company agreed to issue and sell, in a public offering (i) an aggregate of 19,000,000 shares of common stock, $0.0001 par value per share, of the… Filing
- Nov 4, 2026AnnouncementThe disclosure set forth above under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 8.01. Filing
- Nov 4, 2026VoteReported shareholder vote results. Filing
- Oct 30, 2026ListingAnnovis Bio, Inc. received notice from the New York Stock Exchange that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average market capitalization over a consecutive 30… Filing
- Oct 20, 2026AnnouncementDue to a typographical error in the Company’s proxy statement for its annual meeting of stockholders held on June 17, 2026, the Company is filing this Current Report on Form 8-K to correct the disclosure of audit fees. Filing
- Aug 14, 2026ResultsReleased financial results. Filing
- Jul 10, 2026AnnouncementAnnovis Bio, Inc. issued a press release announcing that full enrollment of its pivotal Phase 3 trial (NCT06709014) evaluating buntanetap in patients with early AD has been reached. Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- May 20, 2026AgreementAnnovis Bio, Inc. entered into an Underwriting Agreement, dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter, pursuant to which the Company agreed to issue and sell, in a public offering (i) an aggregate of 7,895,000 shares of common stock, $0.0001 par value per share, of the… Filing
- May 15, 2026ResultsReleased financial results. Filing
- Apr 10, 2026AgreementAnnovis Bio, Inc. entered into (i) an Underwriting Agreement, dated as of April 9, 2026, with Canaccord Genuity LLC, as underwriter, pursuant to which the Company agreed to issue and sell, in an underwritten registered direct offering (i) an aggregate of 5,263,156 shares of common stock, $0.0001… Filing
- Mar 25, 2026LeadershipMark Guerin is no longer employed as as Chief Financial Officer of Annovis Bio, Inc. . Mr. Guerin ’s departure did not arise from any disagreement with the Company or any matter relating to the Company’s operations, policies or practices. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Feb 12, 2026AnnouncementShared information with investors. Filing
- Jan 28, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Annovis Bio financials
Famous investors that hold ANVS
2 of the 50 well-known investors we track reported holding ANVS in their latest 13F filing. The largest position is Jim Simons's, worth $935K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 736,027 | $935K | 0.0% | -27% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 211,892 | $269K | 0.0% | -13% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ANVS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 15, 2026 | Empery Asset Management, LP | 13G/A | 5.0% |
| Oct 15, 2026 | Empery Asset Management, LP | 13G/A | 5.0% |
Questions about Annovis Bio, Inc. (ANVS) stock
Who owns the most ANVS stock?
The largest reported owner of Annovis Bio, Inc. (ANVS) is Empery Asset Management, LP, with 8.5% of the company. In total, 61 funds and institutions reported holding ANVS at the end of Q2 2026, together about 38% of the shares. See the largest owners.
Are ANVS insiders buying or selling?
In the last 12 months, ANVS insiders reported 13 open-market purchases worth $7.1M and no sales. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in ANVS?
As of Oct 30, 2026, 5.36M ANVS shares were sold short, 12.6% of the shares outstanding, down 6.4% from the report before. At the average daily volume of 790,972 shares, buying them all back would take about 6.8 trading days (days to cover). See the history.
Which famous investors hold ANVS?
2 of the 50 well-known investors we track reported ANVS in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $935K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.